|
Ubiquitin aldehyde, (recombinant)
High purity inhibitor of deubiquitinylating enzymes (DUBs).
Synthetically modified recombinant ubiquitin. The modification of the C-terminal glycine carboxyl into an aldehyde results in a potent, highly specific inhibitor of all ubiquitin deconjugating enzymes, including ubiquitin C-terminal hydrolases (UCHs), ubiquitin-specific proteases (USPs) and deubiquitinylating enzymes (DUBs).
Product Specification
Alternative Name: Ub-H
Sequence: Recombinant Ubiquitin (corresponding to UniProt sequence P62988). The C-terminal glycine carboxyl is synthetically modified to an aldehyde.
MW: 8.5kDa
Formulation: Liquid. 1mg/ml aqueous solution containing 0.15M HCl.
Purity: ≥95% (HPLC)
Quality Control: Ubiquitin Aldehyde (recombinant) activity was confirmed by its inhibition of human UCH-L1 and deubiquitinylation of Ubiquitin-AMC (Prod. No. BML-SE211).
Activity: Ubiquitin Aldehyde (recombinant) activity was confirmed by its inhibition of UCH-L3 (BML-UW9745) and USP2 (BML-UW9850) deubiquitinylation of Ubiquitin-AMC (BML-SE211).
Specific Activity: Ki=2.5nM vs. UCH isopeptidase-T.
Application: Ubiquitin Aldehyde (recombinant) is useful in the stabilisation of ubiquitin-protein conjugates in vitro, enhancing their accumulation in cell lysates and tissue extracts. Inhibition of deubiquitinylating enzyme activity by Ubiquitin Aldehyde (recombinant) can be used to identify and confirm such activity and to determine the inhibition kinetics for a particular enzyme. Recommended concentration for maximal inhibition is 2-5µM.
Co-crystallisation of ubiquitin aldehyde with specific deubiquitinylating enzymes (the inhibitor mimics the natural ubiquitin substrate) has also been used to probe enzyme:substrate interactions.
Long Term Storage: +4°C
Use/Stability: Stable for at least two months when stored at 4°C. |